Notice of Interim Results Investor Meeting
Avacta Group plc has announced an investor meeting to discuss its interim results, scheduled for October 15, 2026, at 16:00 BST. The presentation will be delivered by CEO Christina Coughlin and CFO Brian Hahn via Investor Meet Company, and is open to all shareholders. Questions can be submitted in advance by October 14, 2026, at 09:00 BST, or during the live event.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
LONDON and PHILADELPHIA - October 12, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, is pleased to announce that Christina Coughlin, CEO, and Brian Hahn, CFO, will provide a live presentation relating to the Interim Results via Investor Meet Company on 15 Oct 2026, 16:00 BST.
Investors can sign up to Investor Meet Company for free and add to meet Avacta Group Plc via: https://www.investormeetcompany.com/avacta-group-plc/register-investor
Investors who already follow Avacta Group Plc on the Investor Meet Company platform will automatically be invited.
| Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre | CISION® platform. pre | CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre | CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. |
| Our pre | CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre | CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer. |
About FAP-Exd (AVA6103)
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.